Project Grant R01CA296817
Award Date
12/3/24
Completion Date
11/30/29
Dollars Obligated
$687K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94143, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $1,335,041 project grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) to The Regents of the University of California, San Francisco (UCSF) on August 7, 2024. The grant aims to develop metabolic therapy and imaging techniques to improve outcomes and quality of life for patients with diffuse midline gliomas (DMGs), a type of devastating brain cancer in children. Specifically, the project will determine if combined inhibition of...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $655,306 to The Regents of the University of California, San Francisco (UCSF) to develop and evaluate a therapeutic strategy that combines a brain-penetrant glyoxalase 1 (GLO1) inhibitor with radiation for the treatment of isocitrate dehydrogenase-mutant (IDHm) gliomas, one of the deadliest forms of brain cancer. The project aims to mechanistically validate reactive metabolite...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,594,419.00 to The Regents of the University of California, San Francisco (UCSF) to conduct radiopathomic mapping of tumor burden for personalized management of IDH-mutant glioma. The award period runs from September 1, 2025 to August 31, 2028. As a leading academic medical center and research institution, UCSF will leverage its expertise in translational...
This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) will provide $136,412 to the Regents of the University of Michigan to conduct research on defining and interrupting metabolic crosstalk in the glioblastoma (GBM) microenvironment. The primary goals are to: 1) determine mechanistically how metabolite exchange between normal brain cells and GBM cancer cells promotes tumor growth and therapy resistance; 2) investigate the impact of disrupting...
This Project Grant award for $901,906 from the Defense Health Agency supports research to develop "AUTOMATIC RAPID, HIGH RESOLUTION METABOLIC IMAGING FOR IMPROVED MANAGEMENT OF PATIENTS WITH GLIOMA". The funding is provided through the Military Medical Research and Development program (CFDA 12.420) which focuses on biomedical research to address military and veteran health needs. The research, conducted by the Regents of the University of California, San Francisco (UCSF), aims to...
This federal Project Grant award for $142,452.00 was provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The funding supports research to develop novel mRNA-based gene therapies for the treatment of diffuse midline glioma (DMG), a lethal pediatric brain tumor. The principal investigator will optimize the delivery of mRNA using lipid nanoparticles to target the...
This Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) provides $574,000.00 to The Regents of the University of California, San Francisco (UCSF) to conduct research on "Targeting and Imaging Vitamin B5 Metabolism in Diffuse Midline Gliomas". The award period runs from Sep 1, 2025 to Aug 31, 2028. As a leading academic medical center and research institution, UCSF will leverage its expertise in biomedical research,...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) provides $443,354 to the University of Pittsburgh to conduct research on targeting the hexosamine biosynthetic pathway in pediatric brain tumors, specifically diffuse midline gliomas (DMG) harboring the H3K27M mutation. The research aims to investigate how this metabolic pathway supports tumor growth...
This Project Grant award from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $997,410 to Arizona State University, in collaboration with Mayo Clinic Arizona, to develop non-invasive magnetic resonance imaging (MRI) techniques for detecting and differentiating between the invasive neuronal (NEU) and glycolytic/plurimetabolic (GPM) subtypes of high-grade glioma brain tumors. The key objectives are to: Establish and validate...
This Federal Project Grant award for $236,777.00 was provided by the Defense Health Agency to The Regents of the University of California, San Francisco (UCSF) under the Military Medical Research and Development program (CFDA 12.420). The funding supports RAPID HIGH RESOLUTION METABOLIC IMAGING FOR IMPROVED MANAGEMENT OF PATIENTS WITH GLIOMA, a research project aimed at developing advanced imaging techniques to better manage patients with glioma, a type of brain cancer. The award term runs...